Evidence map›Paper›PMID 39708548›Full record

ArticleNeuromuscular disorders : NMD2025

Investigating phenotypic variability patterns in myotonic dystrophy type 2 in a neuromuscular referral center retrospective cohort.

Vincent Picher-Martel, Joseph J Locascio, Kathy Chuang, William S David, Anthony A Amato, Paloma Gonzalez-Perez

Abstract read
In one paragraph

Article in Neuromuscular disorders : NMD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vincent Picher-MartelDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114, United States; Department of Neurology, Brigham Women's Hospital, Harvard Medical School, Boston, MA02115, United States.
Joseph J LocascioDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114, United States; Harvard Catalyst Biostatistical Consulting Group, Boston MA02114, United States.
Kathy ChuangDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114, United States.
William S DavidDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114, United States.
Anthony A AmatoDepartment of Neurology, Brigham Women's Hospital, Harvard Medical School, Boston, MA02115, United States.
Paloma Gonzalez-PerezDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA02114, United States. Electronic address: pgonzalezperez@mgh.harvard.edu.

Funding

Clinical and Non-Invasive Biomarkers of Myotonic DystrophyK23NS118048 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Paloma Gonzalez-Perez · 2023 to 2026
$804k
NINDS NIH HHS K23 NS118048
6 · The paper itself

Abstract

We aimed at investigating the presence of patterns that account for the phenotypic variability in a myotonic dystrophy type 2 (DM2) retrospective cohort at the Mass General Brigham Neuromuscular Centers. We collected the presence or absence of 23 clinical variables at symptom onset and diagnosis (n = 67 patients) and follow-up (n = 37 patients). We first identified set/s of variables (factors or cluster/s) representative of the large research data pool at onset by performing factor analyses, then assigned each patient to the cluster for which they had the highest computed total factor score. Twelve variables grouped into two distinct clusters that, based on their variable content, we named as proximal myotonic myopathy (PROMM)-DM2 or non-PROMM-DM2. Patients assigned to non-PROMM-DM2 more frequently had clinical myotonia and positive family history, and less frequently multiorgan involvement. Most patients (67.2 %) remained assigned to same cluster during disease course and 11 non-PROMM eventually transitioned to PROMM-DM2. Dyslipidemia and early cataracts (both in PROMM-DM2 cluster) were the earliest extramuscular manifestations that occurred during disease course and they accounted for the conversion of up to 8 out of 11 non-PROMM to PROMM converters. Identification of phenotypically homogeneous patient subgroups may help investigating DM2 prognosis and disease biomarkers in future prospective studies.

Indexed as

Myotonic DystrophyAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedPhenotypeRetrospective StudiesYoung AdultCataractsDyslipemiaFactor analysisMyotonic dystrophy type 2 (DM2)Non-PROMM DM2PROMM DM2

Identifiers

PMID39708548
PMCPMC11908914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.